Mesenchymal Stem Cells for The Treatment of Chronic Obstructive Pulmonary Disease

The Safety and Feasibility of UMC119-06 Cell Therapy in Subjects With Chronic Obstructive Pulmonary Disease

The clinical study with UMC119-06 is designed to investigate the safety in patients with Chronic Obstructive Pulmonary Disease. This will be a dose escalation, open label, single-center study in adult with chronic obstructive pulmonary disease. UMC119-06 is ex vivo cultured human umbilical cord tissue-derived mesenchymal stem cells product which is intended for treatment of chronic obstructive pulmonary disease.

Study Overview

• Status: Active, not recruiting
• Conditions: Chronic Obstructive Pulmonary Disease Moderate
• Intervention / Treatment: Biological: UMC119-06

Detailed Description

Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of morbidity and mortality worldwide, predicted to be the third leading cause of death in adults by 2020. Patients with COPD are characterized with airflow limitation and chronic inflammation, which is caused by cigarette smoking, noxious particles or gases. These inhaled irritants will induce inflammation, emphysema and fibrosis though chronic exposure. The current pharmacological treatment of COPD is symptomatic and is mainly based on bronchodilators, such as selective β2-adrenergic agonists (short-and long-acting), anticholinergics, theophylline, or a combination of these drugs. In patients with continuing exacerbations, inhaled corticosteroids (ICSs) may be added in the form of a triple fixed dose combination inhaler that includes ICSs, long-acting β2-agonists (LABA) and inhaled long-acting muscarinic antagonists (LAMA). Although current clinical treatment strategies can improve and stabilize COPD states and quality of life, none of them are able to modify the progressive decline in lung function which is the hallmark of this disease. Therefore, development of new therapeutic modalities to improve the clinical outcomes and prognosis of COPD in adult patients is of urgent need. Among the more innovative, experimental therapies, mesenchymal stromal cells (MSCs) are proposed as a novel therapy with potential in treatment of COPD.

• Study Type: Interventional
• Enrollment (Estimated): 9
• Phase: Phase 1

Contacts and Locations

Study Locations

• Taiwan
  • New Taipei City, Taiwan, 23561
    • Taipei Medical University - Shuang Ho Hospital, Ministry of Health and Welfare.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Subjects of age between ≥ 40 through ≤ 75 years.
• Subjects with diagnosis of COPD based on the Global Initiative for Chronic Obstructive Lung Diseases (GOLD) standard.
• Subjects with a post-bronchodilator FEV1/FVC ratio <0.7.
• Subjects with a post-bronchodilator FEV1 % predicted value ≥ 50% and < 80%.
• Subjects with score ≥ 2 in the modified Medical Research Council Dyspnea Scale (mMRC).
• Subjects with in COPD Assessment Test (CAT) score ≥ 10.
• Subjects with body weight between 40 to 90 kg.
• Subject is willing to provide written informed consent to participate in the study after reading the informed consent form and the information provided.

• Women of child-bearing potential should have a negative urine pregnancy test prior to administration of investigational product, UNLESS they meet the following criteria:

  1. Post-menopausal: 12 months of natural (spontaneous) amenorrhea or 6 months of spontaneous amenorrhea with serum Follicle Stimulating Hormone (FSH) levels > 40 mIU/m, OR;
  2. 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy
• If a male and heterosexually active with a female of childbearing potential, the subject must agree to use a double barrier method of birth control (or must have been surgically sterilized) and to not donate sperm during the study.

Exclusion Criteria:

• Subjects with history of any type of malignancy.
• Subjects with major surgery (body organs that require anesthesia, such as tumor removal, open chest, heart surgery, abdominal surgery, intracranial surgery, or normal surgery for more than 3 hours, etc.) within previous 30 days.
• Subjects who are pregnant (or plan to become pregnant within 3 months of investigational product treatment) or lactating.
• Subjects who have a significant concomitant illness as judged by principal investigator (PI).
• Subjects with known human immunodeficiency virus infection or who are immune compromised.
• Subjects with a known history of alcohol abuse or drug abuse within the 5 years before study treatment administration.
• Subjects who are current smokers.
• Subjects unable to return for follow-up visits for clinical evaluation, laboratory studies, or imaging evaluation.
• Subjects with a history of severe allergic or anaphylactic reactions.
• Subjects with known allergy or hypersensitivity to any component of the formulation or hypersensitivity to any component of the formulation (normal saline and human serum albumin).
• Subjects who have participated in another clinical study of new investigational therapies or have received an investigational therapy within the 12 weeks before study drug administration.
• Subjects with known Alpha-1 antitrypsin deficiency.
• Subjects with current active infection including pulmonary infection, systemic infection or severe local infections.
• Subjects with exacerbation of COPD within the 12 weeks before study treatment administration.

• Subjects who have the following conditions in laboratory tests at screening;

  1. >2 × upper limit of normal (ULN) for alanine aminotransferase (ALT) or aspartate aminotransferase (AST); or
  2. >2 × ULN for serum creatinine.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: UMC119-06; Human Umbilical Cord Derived-Mesenchymal Stem Cells, Single treatment by intravenous infusion.	Biological: UMC119-06; Cohort 1: Low does of UMC119-06 Cohort 2: Medium does of UMC119- 06 Cohort 3: High does of UMC119-06

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The incidence and frequency of adverse events related to administration of UMC119-06.	Incidence of Treatment-Emergent Adverse Events (TEAEs).; Incidence of withdrawals due to Adverse Events(AEs).	3 months from the day of administration

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes in Forced Vital Capacity (FVC).	Improvement in clinical function as assessed by mean change in Forced Vital Capacity (FVC).	15 months from the day of administration.
Changes in Forced Expiratory Volume in One Second (FEV1).	Improvement in clinical function as assessed by mean change in Forced Expiratory Volume in One Second (FEV1).	15 months from the day of administration.
Changes in the ratio of Forced Expiratory Volume in One Second to the Forced Vital Capacity (FEV1/FVC).	Improvement in clinical function as assessed by mean change in the ratio of Forced Expiratory Volume in One Second to the Forced Vital Capacity (FEV1/FVC).	15 months from the day of administration
Changes in exercise performance using 6-min walk test (6MWT).	Improvement in clinical function as assessed by mean change in exercise performance using 6-min walk test (6MWT).	15 months from the day of administration.
Changes in Quality Of Life using St. George's Respiratory Questionnaire Safety (SGRQ).	Scores range from 0 (no impairment) to 100 (maximum impairment), with higher scores indicating more limitation. A decrease in score represents a decrease in disease related symptoms. Improvement in clinical function as assessed by mean change in Quality Of Life using St. George's Respiratory Questionnaire Safety (SGRQ).	15 months from the day of administration.
Changes in modified medical research council (mMRC) -dyspnea scale.	Scores range from 0 (no dyspnea) to 4 (severe dyspnea), with higher scores indicate worse COPD control. Improvement in clinical function as assessed by mean change in modified medical research council (mMRC) -dyspnea scale.	15 months from the day of administration.

Collaborators and Investigators

• Sponsor: Meridigen Biotech Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): June 11, 2020
• Primary Completion (Estimated): December 31, 2023
• Study Completion (Estimated): June 30, 2024

Study Registration Dates

• First Submitted: December 18, 2019
• First Submitted That Met QC Criteria: December 18, 2019
• First Posted (Actual): December 20, 2019

Study Record Updates

• Last Update Posted (Estimated): December 4, 2023
• Last Update Submitted That Met QC Criteria: December 1, 2023
• Last Verified: December 1, 2022

More Information

Terms related to this study

• Keywords: COPD
• Additional Relevant MeSH Terms: Pathologic Processes; Respiratory Tract Diseases; Disease Attributes; Chronic Disease; Lung Diseases; Lung Diseases, Obstructive; Pulmonary Disease, Chronic Obstructive
• Other Study ID Numbers: UMC119-06-COPD-01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No